Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)
Administrator Kamis, 12 Maret 2020 07:06 WIB
ZURICH, SWITZERLAND - EQS Newswire - March 11, 2020 - Xlife Sciences AG tests a new therapy for the treatment of pneumonia caused by coronavirus in cooperation with the Institute of Virology and Immunology (IVI) of the Vetsuisse Faculty of the University of Bern in Switzerland.
Advantages of the therapy are a fundamentally better biovariability and a broad target diversity. The necessary documents have successfully been submitted. (*).